Growth, Body Composition, and Strength of Children With Cystic Fibrosis Treated With Elexacaftor/Tezacaftor/Ivacaftor (ETI)
Pediatric Pulmonology · 2025
DOI: 10.1002/ppul.27463 ↗At a glance
Journal article in Pediatric Pulmonology, 2025. Written by Thomas Boat and 7 co-authors. Institution: Depatment of Pediatrics, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Me…. Major MEDLINE topics: Body Composition, Cystic Fibrosis, Aminophenols, Benzodioxoles. Cited 7 times so far (Crossref); 38 references. Funded by: This work was supported by an independent investigator grant from Vertex Pharmaceuticals. Vertex had no role in collection, analysis or interpretation of data….
Topics: Kinderkrankenpflege
Abstract (original language)
Objective
We prospectively monitored rates of change for growth, body mass and composition, muscle strength, and FEV1 in 6−11‐year‐olds initiating ETI therapy, comparing them to those of US reference children. We assessed factors potentially contributing to rate of change and report ranges of individual variation.
Methods
Body composition was assessed using bioelectrical impedance analysis (BIA), and rates of change were analyzed using linear mixed effects regression models.
Results
At enrollment, median BMI‐Z was 0.6 (IQR: −0.2, 1.1), percent body fat (PBF) was 22.7 (14.0, 31.5), and percent predicted(pp) FEV1 was 100 (90, 106). During ETI treatment, mean Z scores for annualized change rates of BMI (0.02 ± 0.07; p = 0.74), FMI (0.02 ± 0.08; p = 0.76), and FFMI (−0.03 ± 0.07; p = 0.68) were not different from zero. The most rapid weight gain occurred in girls ( p = 0.01), 10−11‐year‐olds ( p < 0.001), and those previously treated with a modulator ( p = 0.005). Individual rates of change varied widely; PBF increased for 15 children (range: 0.7 to 10.0) and decreased for 12 (range: −0.7 to −9.5). Changes in body mass and composition were not significantly associated with changes in ppFEV1; regression coefficients were positive for FFMI (0.83) and SMMI (1.07) and negative for FMI (−0.29).
Conclusion
Healthy, well‐nourished children with CF, as a group, experienced growth and body composition changes similar to those of US children, added muscle mass, and often added more FM than FFM during ETI therapy. Individual variation underscores the need for body composition monitoring and interventions that promote healthy physical maturation for all during ETI therapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Depatment of Pediatrics, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Depatment of Pediatrics, Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Depatment of Pediatrics, Division of biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Division of Pulmonary Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Department of Pediatrics, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Depatment of Pediatrics, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Funding
- This work was supported by an independent investigator grant from Vertex Pharmaceuticals. Vertex had no role in collection, analysis or interpretation of data…
Cite
APA
Boat, T., Hossain, M. M., Nakamura, A., Hjelm, M., Hardie, W., Wackler, M., Amato, A., & Dress, C. (2025). Growth, Body Composition, and Strength of Children With Cystic Fibrosis Treated With Elexacaftor/Tezacaftor/Ivacaftor (ETI). Pediatric Pulmonology. https://doi.org/10.1002/ppul.27463
Vancouver
Boat T, Hossain MM, Nakamura A, Hjelm M, Hardie W, Wackler M, et al. Growth, Body Composition, and Strength of Children With Cystic Fibrosis Treated With Elexacaftor/Tezacaftor/Ivacaftor (ETI). Pediatric Pulmonology. 2025. doi:10.1002/ppul.27463
BibTeX
@article{Boat2025,
author = {Boat, Thomas and Hossain, Md Monir and Nakamura, Aisaku and Hjelm, Michelle and Hardie, William and Wackler, Matthew and Amato, Alyssa and Dress, Carolyn},
title = {Growth, Body Composition, and Strength of Children With Cystic Fibrosis Treated With Elexacaftor/Tezacaftor/Ivacaftor (ETI)},
journal = {Pediatric Pulmonology},
year = {2025},
doi = {10.1002/ppul.27463}
}
EUVIMED